Pharmaceutical fraud and abuse in the United States, 1996-2010

Archives of Internal Medicine

Volumn 171, Issue 16, 2011, Pages 1503-1506

  Qureshi, Zaina P ^a   Sartor, Oliver ^c   Xirasagar, Sudha ^a   Liu, Ying ^b   Bennett, Charles L ^a,d  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b INDIANA UNIVERSITY   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BILLING AND CLAIMS; DRUG ABUSE; DRUG INDUSTRY; DRUG MARKETING; FRAUD; HUMAN; LAW SUIT; LEGAL LIABILITY; MEDICOLEGAL ASPECT; PRIORITY JOURNAL; UNITED STATES;

DRUG INDUSTRY; FRAUD; HUMANS; PRESCRIPTION DRUGS; UNITED STATES;

EID: 80052714283     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.397     Document Type: Article

References (5)

1. Almashat S, Preston C, Waterman T, Wolfe S. Rapidly increasing criminal and civil monetary penalties against the pharmaceutical industry: 1991 to 2010. http://www.citizen.org/documents/rapidlyincreasingcriminalandcivilpenalties.pdf. Accessed April 28, 2011.
2. Kesselheim AS, Studdert DM. Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996 to 2005. Ann Intern Med. 2008;149(5):342-349.
3. False Claims Act. 31 USC §3729-3733.
4. Mello MM, Studdert DM, Brennan TA. Shifting terrain in the regulation of off-label promotion of pharmaceuticals. N Engl J Med. 2009;360(15):1557-1566.
5. Spitzer K. The administration targets a drug CEO in a troubling precedent. 2011. http://online.wsj.com/article. Accessed April 28, 2011.